The fragile site at 16q22, distamycin A, and the normal pachytene structure of chromosome 16: some possible interrelationships

1981 ◽  
Vol 30 (1) ◽  
pp. 63-64 ◽  
Author(s):  
D.A. Hungerford
Keyword(s):  
Fragile Site ◽  
Chromosome 16 ◽  
Distamycin A

Demonstration of a heritable fragile site in human chromosome 16 with distamycin A

1980 ◽  
Vol 28 (1-2) ◽  
pp. 87-94 ◽  
Author(s):  
M. Schmid ◽  
C. Klett ◽  
A. Niederhofer
Keyword(s):  
Human Chromosome ◽  
Fragile Site ◽  
Chromosome 16 ◽  
Distamycin A

The FRA16D common chromosomal fragile site co-localizes with a region of LOH on chromosome 16 in hepatocellular carcinoma

2001 ◽  
Vol 120 (5) ◽  
pp. A360-A361
Author(s):  
Ileana Aderca ◽  
Damian P. Montoya ◽  
Kurt A. Krummel ◽  
David M. Nagorney ◽  
David I. Smith ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Fragile Site ◽  
Chromosome 16

The fragile site on chromosome 16 (q21q22)

1980 ◽  
Vol 55 (1) ◽  
pp. 19-22 ◽  
Author(s):  
F. Shabtai ◽  
S. Bichacho ◽  
I. Halbrecht
Keyword(s):  
Fragile Site ◽  
Chromosome 16

Do leukemia patients with chromosome 16 inversion—Inv(16)(p13q22)—Have a rare fragile site at 16q22?

1988 ◽  
Vol 31 (1) ◽  
pp. 31-34 ◽  
Author(s):  
Kazuma Ohyashiki ◽  
Junko H. Ohyashiki ◽  
Keisuke Toyama ◽  
Hisao Ito
Keyword(s):  
Fragile Site ◽  
Chromosome 16

Familial fragility on chromosome 16 (Fra 16q22) enhanced by both interferon and distamycin A

1983 ◽  
Vol 63 (4) ◽  
pp. 341-344 ◽  
Author(s):  
Fiorella Shabtai ◽  
Dvora Klar ◽  
S. Bichacho ◽  
J. Hart ◽  
I. Halbrecht
Keyword(s):  
Chromosome 16 ◽  
Distamycin A

INTERFERON-INDUCIBLE FRAGILE SITE ON CHROMOSOME 16

The Lancet ◽  
1981 ◽  
Vol 317 (8211) ◽  
pp. 108 ◽  
Author(s):  
Frederick Hecht ◽  
Barbara Kaiser-Mccaw ◽  
PeterB. Jacky
Keyword(s):  
Fragile Site ◽  
Chromosome 16

Heritable Fragile Site on Chromosome 16: Probable Localization of Haptoglobin Locus in Man

Science ◽  
1970 ◽  
Vol 170 (3953) ◽  
pp. 85-87 ◽  
Author(s):  
R. E. Magenis ◽  
F. Hecht ◽  
E. W. Lovrien
Keyword(s):  
Fragile Site ◽  
Chromosome 16

Abnormalities of 16q in Multiple Myeloma Are Associated with Poor Prognosis: 500K Gene Mapping and Expression Correlations Identify Two Potential Tumor Suppressor Genes, WWOX and CYLD.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 110-110
Author(s):  
Matthew W. Jenner ◽  
Paola E. Leone ◽  
Brian A. Walker ◽  
David C. Johnson ◽  
Laura Chiecchio ◽  
...  
Keyword(s):  
Tumor Suppressor ◽  
Gene Mapping ◽  
Tumor Suppressor Genes ◽  
Poor Prognosis ◽  
Fragile Site ◽  
Fragile Sites ◽  
Common Fragile Site ◽  
Chromosome 16 ◽  
Common Fragile Sites ◽  
Potential Tumor Suppressor

Abstract Abnormalities of 16q are important recurrent events in multiple myeloma (MM). We performed FISH on CD138 selected plasma cells from 701 newly diagnosed MM patients from the LRF UKMF cytogenetics database. Gene mapping, including paired normal controls, and gene expression analysis was performed on 55 cases using the Affymetrix Human Mapping 500K Array Set and U133 Plus 2.0 Arrays respectively. 16q deletion (del16q) was identified by FISH using probes for cMAF (Abbott Diagnostics) in 131/701 cases (18.7%) and was significantly associated with deletion 17p (16.5% vs. 8.9%, p=0.006), deletion 13 (60.8% vs. 48.5%, p=0.009), deletion of IgH (22.1% vs. 11.1%, p=0.0003) and non-hyperdiploid status (58.3% vs. 42.7%, p=0.006). Del16q showed a trend to poor overall survival, mean survival 43 vs. 61 months (p=0.09), and was associated with significantly worse survival in combination with t(4;14) compared with either t(4;14) or del16q alone, mean survival 15 vs. 26 vs. 45 months respectively (p=0.006). t(14;16) was identified by FISH in 31/701 cases (4.4%) and was associated with poor prognosis, mean survival 29 vs. 54 months (p=0.005). Mapping arrays revealed loss of heterozygosity (LOH) involving all or part of 16q in 20 of 55 cases (36%) in 3 distinct patterns: uniparental disomy (UPD) of chromosome 16 or 16q in 4/55 cases (7%); deletion of chromosome 16 or the whole of 16q in 11/55 cases (20%); and interstitial deletion of small regions of 16q in 5/55 cases (10%), focused on 16q12, the location of CYLD, and 16q23, the location of WWOX. 16q LOH was distributed across translocation groups but was identified in all 4 mapping cases containing 17p deletion, supporting the association identified by FISH. As WWOX is the site of the common fragile site FRA16D and deletions at common fragile sites have been associated with DNA instability in human cancers, we assessed this using gene mapping in these 55 MM cases. Although deletions spanning other common fragile sites were identified, they were not restricted to those with 16q LOH. However, in 2 t(14;16) cases, hemizygous deletions of approximately 100kb could be identified within WWOX at the presumed translocation breakpoint. One of the t(14;16) cases had a similar hemizygous deletion within FHIT, another tumor suppressor gene located within common fragile site FRA3B, consistent with findings in other cancer types. Cases with 16q LOH or t(14;16) all had significantly reduced WWOX expression relative to cases without 16q abnormalities, confirming gene inactivation by either LOH or translocation. Cases with 16q LOH also had significantly reduced expression of two other potential tumor suppressor genes located on 16q, CYLD and RBL2. In summary, our data confirms the adverse prognosis associated with 16q translocation or deletion. Array data reveals 16q LOH occurs due to deletion or UPD with two regions involved, one defined by CYLD and the other by WWOX. WWOX is also inactivated by translocation and is associated with interstitial deletions at this and other common fragile sites. WWOX is a likely candidate gene in MM pathogenesis because of its interaction with TP53 and CYLD via its effects on NF-κB.

Fragile site long arm chromosome 16

1979 ◽  
Vol 48 (1) ◽  
pp. 131-134 ◽  
Author(s):  
K. S�rensen ◽  
J. Nielsen ◽  
V. Holm ◽  
J. Haahr
Keyword(s):  
Fragile Site ◽  
Chromosome 16
Sign in / Sign up

Export Citation Format

Share Document